The combination of CB and DDP can be considered an effective strategy to increase the sensitivity of DDP‐resistant lung cancer cells to DDP by inhibiting the PI3K/AKT and MAPK/ERK pathways. The gene discussed is AKT1; the disease is lung carcinoma.